Jennifer B. Marks
Publications by Year
Research Areas
Diabetes Management and Research, Diabetes and associated disorders, Pancreatic function and diabetes, Diabetes, Cardiovascular Risks, and Lipoproteins, Diabetes Treatment and Management
Most-Cited Works
- → An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes(2019)1,055 cited
- → Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function(2009)1,055 cited
- → Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial(2011)592 cited
- → Validation of the insulin sensitivity index (ISI0,120): comparison with other measures(2000)474 cited
- → Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial(2011)365 cited
- → Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials(2013)352 cited
- → Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals(2021)337 cited
- → B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results(2013)275 cited
- → Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes(2003)251 cited
- → Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment(2013)202 cited